453 related articles for article (PubMed ID: 20395162)
1. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
2. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
3. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
4. Advances in oncolytic viral therapy.
Woo Y; Adusumilli PS; Fong Y
Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
[TBL] [Abstract][Full Text] [Related]
5. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
7. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Nguyên TL; Abdelbary H; Arguello M; Breitbach C; Leveille S; Diallo JS; Yasmeen A; Bismar TA; Kirn D; Falls T; Snoulten VE; Vanderhyden BC; Werier J; Atkins H; Vähä-Koskela MJ; Stojdl DF; Bell JC; Hiscott J
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14981-6. PubMed ID: 18815361
[TBL] [Abstract][Full Text] [Related]
8. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
9. Novel oncolytic viruses: riding high on the next wave?
Stanford MM; Bell JC; Vähä-Koskela MJ
Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
[TBL] [Abstract][Full Text] [Related]
10. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
11. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
12. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
15. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
Breitbach CJ; Reid T; Burke J; Bell JC; Kirn DH
Cytokine Growth Factor Rev; 2010; 21(2-3):85-9. PubMed ID: 20472490
[TBL] [Abstract][Full Text] [Related]
16. Potentiating oncolytic viruses by targeted drug intervention.
Mahoney DJ; Stojdl DF
Curr Opin Mol Ther; 2010 Aug; 12(4):394-402. PubMed ID: 20677090
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.
Pei DS; Zheng JN
Expert Opin Biol Ther; 2010 Jun; 10(6):917-26. PubMed ID: 20402550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]